184 related articles for article (PubMed ID: 1980313)
1. Challenging the pyramid. A new look at therapeutic approaches for rheumatoid arthritis. Earlier intervention with second line therapies.
Ward JR
J Rheumatol Suppl; 1990 Nov; 25():18-23. PubMed ID: 1980313
[TBL] [Abstract][Full Text] [Related]
2. DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
Simon LS
Int J Clin Pract; 2000 May; 54(4):243-9. PubMed ID: 10912314
[TBL] [Abstract][Full Text] [Related]
3. Challenging the pyramid. A new look at terapeutic approaches for rheumatoid arthritis. Patient selection.
Katz WA
J Rheumatol Suppl; 1990 Nov; 25():39-41. PubMed ID: 1980315
[TBL] [Abstract][Full Text] [Related]
4. Leflunomide for rheumatoid arthritis.
Drug Ther Bull; 2000 Jul; 38(7):52-4. PubMed ID: 11027115
[TBL] [Abstract][Full Text] [Related]
5. Response to therapy in rheumatoid arthritis is influenced by immediately prior therapy.
Fries JF; Williams CA; Singh G; Ramey DR
J Rheumatol; 1997 May; 24(5):838-44. PubMed ID: 9150069
[TBL] [Abstract][Full Text] [Related]
6. Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996.
Ward MM; Fries JF
J Rheumatol; 1998 Mar; 25(3):408-16. PubMed ID: 9517756
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing length of time taking methotrexate in rheumatoid arthritis.
Ortendahl M; Schettler JD; Fries JF
J Rheumatol; 2000 May; 27(5):1139-47. PubMed ID: 10813279
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
Hurst S; Kallan MJ; Wolfe FJ; Fries JF; Albert DA
J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
[TBL] [Abstract][Full Text] [Related]
9. Challenging the therapeutic pyramid: a new look at treatment strategies for rheumatoid arthritis.
Wilske KR; Healey LA
J Rheumatol Suppl; 1990 Nov; 25():4-7. PubMed ID: 2273521
[TBL] [Abstract][Full Text] [Related]
10. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts.
Wolfe F; Hawley DJ; Cathey MA
J Rheumatol; 1990 Aug; 17(8):994-1002. PubMed ID: 1976811
[TBL] [Abstract][Full Text] [Related]
11. Nonsteroidal peptic damage in rheumatoid patients receiving second-line drugs.
Taha AS; Capell HA; Sturrock RD; Russell RI
Am J Gastroenterol; 1991 Nov; 86(11):1588-91. PubMed ID: 1683150
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
Furst DE; Saag K; Fleischmann MR; Sherrer Y; Block JA; Schnitzer T; Rutstein J; Baldassare A; Kaine J; Calabrese L; Dietz F; Sack M; Senter RG; Wiesenhutter C; Schiff M; Stein CM; Satoi Y; Matsumoto A; Caldwell J; Harris RE; Moreland LW; Hurd E; Yocum D; Stamler DA
Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503
[TBL] [Abstract][Full Text] [Related]
13. [The role of the conventional drugs in the treatment of rheumatoid arthritis].
Fantini F
Recenti Prog Med; 2003; 94(7-8):330-8. PubMed ID: 12868241
[TBL] [Abstract][Full Text] [Related]
14. [Comparative study of the effects of auranofin and aurothiomalate on laboratory and clinical indicators in patients with rheumatoid arthritis].
Vlak T; Stambuk B
Reumatizam; 1998; 46(1):7-19. PubMed ID: 9921004
[TBL] [Abstract][Full Text] [Related]
15. [Gold preparations in therapy of rheumatoid and psoriatic arthritis].
Nasonova VA; Lukina GV; Sigidin IaA; Badokin VV
Ter Arkh; 2003; 75(5):88-90. PubMed ID: 12847908
[No Abstract] [Full Text] [Related]
16. Safety of combination therapy with hydroxychloroquine, gold sodium thiomalate and methotrexate in early rheumatoid arthritis.
Biasi D; Caramaschi P; Carletto A; Pacor ML; Bambara LM
Rev Rhum Engl Ed; 1997; 64(7-9):521-2. PubMed ID: 9338941
[No Abstract] [Full Text] [Related]
17. [Methotrexate and non-steroidal anti-inflammatory agent combination in rheumatoid arthritis].
Bertin P; Carpentier N; Vergne P; Bonnet C; Bannwarth B; Dehais J; Treves R
Therapie; 1997; 52(2):133-7. PubMed ID: 9231508
[TBL] [Abstract][Full Text] [Related]
18. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
[TBL] [Abstract][Full Text] [Related]
19. Variability in individual responses of 532 patients with rheumatoid arthritis to first-line and second-line drugs.
Pincus T; Callahan LF
Agents Actions Suppl; 1993; 44():67-75. PubMed ID: 8103964
[TBL] [Abstract][Full Text] [Related]
20. Current concepts in clinical therapeutics: disease-modifying drugs for rheumatoid arthritis.
Pugh MC; Pugh CB
Clin Pharm; 1987 Jun; 6(6):475-91. PubMed ID: 3319362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
